肿瘤患者的心律失常——2022年欧洲心脏病学会新指南背景下的流行病学、危险因素及管理
Cardiac Arrhythmias in Oncological Patients-Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines.
作者信息
Gawlik Michał, Zimodro Jakub Michal, Gąsecka Aleksandra, Filipiak Krzysztof J, Szmit Sebastian
机构信息
1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy in Warsaw, Warsaw, Poland.
出版信息
Curr Oncol Rep. 2023 Oct;25(10):1107-1115. doi: 10.1007/s11912-023-01445-x. Epub 2023 Aug 17.
PURPOSE OF REVIEW
To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology.
RECENT FINDINGS
One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity.
综述目的
在欧洲心脏病学会2022年心脏肿瘤学新指南的背景下，提供肿瘤患者心律失常的流行病学、危险因素及管理方面的最新进展。
最新发现
不同化疗药物的副作用之一是其促心律失常活性。心房和室性心律失常可能由癌症本身或抗癌治疗诱发。最近的研究报道了诸如BRAF和MEK抑制剂或CAR-T疗法等有前景的疗法的心脏毒性活性。肿瘤患者心律失常的危险因素与心血管疾病的危险因素重叠，但有几类抗癌药物会增加心脏毒性风险。了解肿瘤治疗相关风险并知道在发生心脏毒性时如何应对至关重要。
Zotero 插件